Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
Phase 1b Multiple Ascending Dose Study of BMS-833923 (XL139) Administered in Combination With Cisplatin and Capecitabine as First-Line Therapy in Patients With Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
Phase 1b Multiple Ascending Dose Study of BMS-833923 (XL139) Administered in Combination With Cisplatin and Capecitabine as First-Line Therapy in Patients With Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases
A PhaseI/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 Inhibitor AZD1480 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF
Status: Archived
Clinical Research Facility
mi
from
Bronx, NY
Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases
A PhaseI/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 Inhibitor AZD1480 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bronx, NY
Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases
A PhaseI/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 Inhibitor AZD1480 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF
Status: Archived
Clinical Research Facility
mi
from
Houston, TX
Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases
A PhaseI/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 Inhibitor AZD1480 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Houston, TX
A Study of MM-111 in Patients With Advanced Her2 Positive Cancers
A Phase 1-2 and Pharmacologic Study of MM-111 in Patients With Advanced, Refractory Her2 Positive Cancers
Status: Archived
Fox Chase Cancer Center
mi
from
Philadephia, PA
A Study of MM-111 in Patients With Advanced Her2 Positive Cancers
A Phase 1-2 and Pharmacologic Study of MM-111 in Patients With Advanced, Refractory Her2 Positive Cancers
Status: Archived
Updated: 1/1/1970
Fox Chase Cancer Center
mi
from
Philadephia, PA
A Study of MM-111 in Patients With Advanced Her2 Positive Cancers
A Phase 1-2 and Pharmacologic Study of MM-111 in Patients With Advanced, Refractory Her2 Positive Cancers
Status: Archived
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
A Study of MM-111 in Patients With Advanced Her2 Positive Cancers
A Phase 1-2 and Pharmacologic Study of MM-111 in Patients With Advanced, Refractory Her2 Positive Cancers
Status: Archived
Updated: 1/1/1970
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Clinical Research Facility
mi
from
San Diego, CA
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
San Diego, CA
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Clinical Research Facility
mi
from
Denver, CO
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Denver, CO
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Clinical Research Facility
mi
from
Newark, DE
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Newark, DE
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Clinical Research Facility
mi
from
Bronx, NY
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bronx, NY
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Clinical Research Facility
mi
from
Asheville, NC
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Asheville, NC
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Clinical Research Facility
mi
from
Allentown, PA
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Allentown, PA
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Clinical Research Facility
mi
from
Chattanooga, TN
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Chattanooga, TN
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Clinical Research Facility
mi
from
Bellingham, WA
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bellingham, WA
Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods of Treatment
A Phase I Trial of p28 (Cell Penetrating Peptide) in the Treatment of Refractory Solid Tumors
Status: Archived
University of Illinois College of Medicine
mi
from
Chicago, IL
Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods of Treatment
A Phase I Trial of p28 (Cell Penetrating Peptide) in the Treatment of Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
University of Illinois College of Medicine
mi
from
Chicago, IL
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Wilshire Oncology Medical Group
mi
from
La Verne, CA
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Wilshire Oncology Medical Group
mi
from
La Verne, CA
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Eastern Connecticut Hematology & Oncology
mi
from
Norwich, CT
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Eastern Connecticut Hematology & Oncology
mi
from
Norwich, CT
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Aventura Hospital and Medical Center
mi
from
Aventura, FL
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Aventura Hospital and Medical Center
mi
from
Aventura, FL
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Florida Cancer Specialists
mi
from
Fort Myers, FL
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Florida Cancer Specialists
mi
from
Fort Myers, FL
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Mercy Hospital
mi
from
Portland, ME
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Mercy Hospital
mi
from
Portland, ME
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Oncology Hematology Care
mi
from
Cincinnati, OH
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Oncology Hematology Care
mi
from
Cincinnati, OH
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Mid Ohio Oncology/Hematology, Inc.
mi
from
Columbus, OH
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Mid Ohio Oncology/Hematology, Inc.
mi
from
Columbus, OH
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Fairfax Northern Virginia Hem-Onc
mi
from
Fairfax, VA
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Fairfax Northern Virginia Hem-Onc
mi
from
Fairfax, VA
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Virginia Cancer Institute
mi
from
Richmond, VA
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Virginia Cancer Institute
mi
from
Richmond, VA
Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
A Phase II Clinical Trial of Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
A Phase II Clinical Trial of Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
A Phase II Clinical Trial of Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
Status: Archived
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
A Phase II Clinical Trial of Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
Status: Archived
Updated: 1/1/1970
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
A Phase II Clinical Trial of Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
Status: Archived
Dana-Farber Cancer Institute
mi
from
Boston, MA
Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
A Phase II Clinical Trial of Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
mi
from
Boston, MA
ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome
A Phase 1 Study of Oral ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome
Status: Archived
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome
A Phase 1 Study of Oral ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome
Status: Archived
Updated: 1/1/1970
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome
A Phase 1 Study of Oral ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome
Status: Archived
Winship Cancer Institute of Emory University
mi
from
Egleston, GA
ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome
A Phase 1 Study of Oral ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome
Status: Archived
Updated: 1/1/1970
Winship Cancer Institute of Emory University
mi
from
Egleston, GA
ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome
A Phase 1 Study of Oral ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome
Status: Archived
M. D. Anderson Cancer Center
mi
from
Orlando, FL
ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome
A Phase 1 Study of Oral ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome
Status: Archived
Updated: 1/1/1970
M. D. Anderson Cancer Center
mi
from
Orlando, FL
FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer
Anti-[18F]FACBCPET_CT for the Characterization of Primary Prostate Cancer
Status: Archived
Emory Umiversity School of Medicine
mi
from
Atlanta, GA
FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer
Anti-[18F]FACBCPET_CT for the Characterization of Primary Prostate Cancer
Status: Archived
Updated: 1/1/1970
Emory Umiversity School of Medicine
mi
from
Atlanta, GA
A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer
A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer
Status: Archived
Memorial Sloan Kettering
mi
from
New York City, NY
A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer
A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer
Status: Archived
Updated: 1/1/1970
Memorial Sloan Kettering
mi
from
New York City, NY
A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer
A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer
Status: Archived
Cornell University, Weill Medical College
mi
from
New York, NY
A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer
A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer
Status: Archived
Updated: 1/1/1970
Cornell University, Weill Medical College
mi
from
New York, NY
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
A Test-retest Study to Assess Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of AH111585 (18F) Injection.
Status: Archived
101 Carnegie Center
mi
from
Princeton, NJ
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
A Test-retest Study to Assess Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of AH111585 (18F) Injection.
Status: Archived
Updated: 1/1/1970
101 Carnegie Center
mi
from
Princeton, NJ
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
A Phase II Trial of Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
Status: Archived
Duke Univ Med Ctr
mi
from
Durham, NC
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
A Phase II Trial of Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
mi
from
Durham, NC
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
A Phase II Trial of Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
Status: Archived
Oregon Health and Science University
mi
from
Portland, OR
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
A Phase II Trial of Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
Oregon Health and Science University
mi
from
Portland, OR
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
A Phase II Trial of Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
Status: Archived
University of Washington; UW Medical Center
mi
from
Seattle, WA
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
A Phase II Trial of Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
University of Washington; UW Medical Center
mi
from
Seattle, WA
Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments
Phase 1 Study of MCP-3100 in Patients With Refractory or Relapsed Cancer
Status: Archived
Nevada Cancer Institute
mi
from
Las Vegas, NV
Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments
Phase 1 Study of MCP-3100 in Patients With Refractory or Relapsed Cancer
Status: Archived
Updated: 1/1/1970
Nevada Cancer Institute
mi
from
Las Vegas, NV
Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments
Phase 1 Study of MCP-3100 in Patients With Refractory or Relapsed Cancer
Status: Archived
Fox Chase Cancer Center
mi
from
Philadephia, PA
Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments
Phase 1 Study of MCP-3100 in Patients With Refractory or Relapsed Cancer
Status: Archived
Updated: 1/1/1970
Fox Chase Cancer Center
mi
from
Philadephia, PA
Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments
Phase 1 Study of MCP-3100 in Patients With Refractory or Relapsed Cancer
Status: Archived
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments
Phase 1 Study of MCP-3100 in Patients With Refractory or Relapsed Cancer
Status: Archived
Updated: 1/1/1970
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Study of Metabolic Syndrome in Adolescent and Young Adult Survivors of Childhood Leukemia Who Have Undergone Stem Cell Transplant
Metabolic Syndrome Following Transplant for Leukemia
Status: Archived
Children's Hospital - Boston
mi
from
Boston, MA
Study of Metabolic Syndrome in Adolescent and Young Adult Survivors of Childhood Leukemia Who Have Undergone Stem Cell Transplant
Metabolic Syndrome Following Transplant for Leukemia
Status: Archived
Updated: 1/1/1970
Children's Hospital - Boston
mi
from
Boston, MA
Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer
A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer
Status: Archived
Dana-Farber Cancer Institute
mi
from
Boston, MA
Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer
A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
mi
from
Boston, MA
Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer
A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer
Status: Archived
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer
A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer
Status: Archived
Updated: 1/1/1970
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer
A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer
Status: Archived
Roswell Park Cancer Center Institute
mi
from
Buffalo, NY
Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer
A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer
Status: Archived
Updated: 1/1/1970
Roswell Park Cancer Center Institute
mi
from
Buffalo, NY
Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer
A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer
A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX